Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Sichuan Cancer Hospital and Research Institute clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sichuan Cancer Hospital and Research Institute as lead sponsor. Synced 17 Nov 2026
18Current trials
8Recruiting now
9Drugs in these trials
1Trial register
At a glance

Sichuan Cancer Hospital and Research Institute is the lead sponsor of 18 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Carboplatin, Paclitaxel and Tislelizumab. The most-studied condition is Esophageal Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting844%
  • Not yet open844%
  • Active, closed16%
  • By invitation16%

Trials by phase

  • Not applicable633%
  • Phase 2528%
  • Observational422%
  • Phase 3211%
  • Phase 1/216%
01

Clinical trials sponsored by Sichuan Cancer Hospital and Research Institute

18 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591 · ClinicalTrials.gov ↗ · NSCLC
Phase 2 Recruiting 2024-08 China
Shared Decision Making in Patients With Lung Cancer
NCT05191485 · ClinicalTrials.gov ↗ · Surgery, Lung Adenocarcinoma
Observational Recruiting 2023-02 China
Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
NCT06697938 · ClinicalTrials.gov ↗ · Breast Cancer
Not applicable Recruiting 2024-11 China
Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
NCT05508347 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
Phase 2 Recruiting 2022-04 China
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
NCT06361589 · ClinicalTrials.gov ↗ · ALK-positive Non-small Cell Lung Cancer, Real World Study
Observational Recruiting 2024-05 China
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
NCT06244537 · ClinicalTrials.gov ↗ · Safety and Efficacy
Not applicable Recruiting 2024-04 China
A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms
NCT05526534 · ClinicalTrials.gov ↗ · Gynecologic Surgery, High-flow Nasal Cannula, Post-operative Pulmonary Complications
Not applicable Recruiting 2022-11 China
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
NCT05173272 · ClinicalTrials.gov ↗ · Cervical Cancer
Phase 3 Recruiting 2023-07 China
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484 · ClinicalTrials.gov ↗ · Lung Metastatic Nasopharyngeal Carcinoma
Not applicable Not yet open 2025-07 China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 2 Not yet open 2026-08 China
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07561983 · ClinicalTrials.gov ↗ · Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy
Phase 2 Not yet open 2026-05 China
Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery
NCT06860685 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)
Phase 1/2 Not yet open 2025-03 China
Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy
NCT07172087 · ClinicalTrials.gov ↗ · Colorectal Cancer
Not applicable Not yet open 2025-09 China
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
NCT05244798 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
Phase 3 Not yet open 2022-11 China
Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial
NCT06717854 · ClinicalTrials.gov ↗ · Low Anterior Resection Syndrome
Not applicable Not yet open 2025-03 China
Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer
NCT07590596 · ClinicalTrials.gov ↗ · Pulmonary Nodule, Suspected Lung Cancer, Preoperative Decision-Making
Observational Not yet open 2026-05 China
Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients
NCT06761534 · ClinicalTrials.gov ↗ · Geriatric Assessment, Geriatric Patients, Patients With Cancer
Observational By invitation 2025-02 China
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
NCT05189730 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
Phase 2 Active, closed 2021-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sichuan Cancer Hospital and Research Institute trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sichuan Cancer Hospital and Research Institute trials

29 conditions
Esophageal Squamous Cell Carcinoma2Lung Metastatic Nasopharyngeal Carcinoma1Non-Small Cell Lung Cancer1NSCLC1Unresectable Stage III Non-small Cell Lung Cancer1Tislelizumab1Chemotherapy1Chemoembolization, Therapeutic1Surgery1Lung Adenocarcinoma1Colorectal Cancer (CRC)1Colorectal Cancer1Breast Cancer1Nasopharyngeal Carcinoma1ALK-positive Non-small Cell Lung Cancer1Real World Study1Safety and Efficacy1Gynecologic Surgery1High-flow Nasal Cannula1Post-operative Pulmonary Complications1Low Anterior Resection Syndrome1Geriatric Assessment1Geriatric Patients1Patients With Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China188

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Esophageal Squamous Cell Carcinoma

SponsorTrials
Shanghai Zhongshan Hospital4
Hebei Medical University Fourth Hospital4
Tang-Du Hospital4
Anhui Provincial Hospital4
Peking University4
Zhejiang Cancer Hospital3
Henan Cancer Hospital3
Fujian Medical University Union Hospital2
Shanghai Cancer Hospital, China1
Affiliated Cancer Hospital of Shantou University Medical College1

Sponsors with the most current trials registered for this condition.

06

Questions about Sichuan Cancer Hospital and Research Institute trials

How many clinical trials does Sichuan Cancer Hospital and Research Institute sponsor?

Sichuan Cancer Hospital and Research Institute is the lead sponsor of 18 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Sichuan Cancer Hospital and Research Institute trials recruiting?

Yes. 8 of its 18 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan Cancer Hospital and Research Institute testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Carboplatin (3), Paclitaxel (2), Tislelizumab (2), Cadonilimab (1) and Cisplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.